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Abstract. A new type of blood component separator (BCS) was used for the isolation of 
hematopoietic progenitor cells from human bone marrow aspirates. The BCS was filled with 
100-150 ml bone marrow and centrifuged to prepare a buffy coat. This buffy coat was isolated 
in 10-15% of the original bone marrow volume and contained 64 ±  8% of the nucleated cells 
(NC). Morphological examination revealed that the buffy coat was highly enriched for 
myeloblasts, promyelocytes, lymphocytes and monocytes, v/hereas the contamination with 
granulocytes was reduced to 46 ±  8% of the granulocytes initially present in the bone marrow 
suspension. In addition the contamination with red blood cells (RBC) was very low; the 
buffy coat contained only 6 ±2% of the RBC. Furthermore it was demonstrated by means of 
colony assays that the buffy coat was highly enriched for hematopoietic progenitor cells. It 
contained 91 ±  6% of the granulocyte/monocyte progenitor cells (CFU-GM) and 87 ±  9% of 
the erythroid progenitor cells (BFU-E). These results are comparable to those obtained with 
continuous or semicontinuous blood cell processors. The advantages of the BCS is that it is a 
simple and inexpensive apparatus which fits in a normal blood bank centrifuge. It permits 
efficient preparation and isolation of a buffy coat from human bone marrow without sub­
stantial loss of hematopoietic progenitor cells.
Introduction
Bone marrow failure, as a result of anti­
cancer therapy, is often treated by reinfusing 
cryopreserved autologous bone marrow. To 
facilitate storage, reconstitution and in vitro
manipulation, various methods have been 
developed to concentrate the marrow 
cells.
Most investigators use semicontinuous 
Weiner  et al.? 1977; M a and Biggs, 1982; 
Van de O uw elandet al., 1982] or continuous
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[Gilmore et al., 1983] centrifugation proce­
dures to prepare a buffy coat from the bone 
marrow suspension to remove red blood 
cells (RBC) and granulocytes. However, 
since these techniques are rather expensive 
and require skillful personnel they are gen­
erally applied in the larger medical centers 
only.
Density gradient centrifugation has also 
been used to isolate the mononuclear cell 
fraction (inluding the hematopoietic pro­
genitor cells) from bone marrow suspensions 
[Dicke et al., 1968; Wells et al., 1979]. How­
ever, the number of cells that can be applied 
to a density gradient is limited. Gilmore et al. 
[1982] solved this problem by first preparing 
a buffy coat in an IBM 2991 blood cell pro­
cessor to reduce the cell number and subse­
quently isolating the mononuclear cells us­
ing Ficoll/metrizoate in the same apparatus.
We recently developed a prototype of an 
inexpensive blood component separator 
(BCS) [F igdorti  al., 1982a, b]. This sandglass 
resembling apparatus fitted in a normal pre­
parative bloodbank centrifuge and was used 
to prepare buffy coats from peripheral 
blood. After centrifugation, the buffy coat 
was fractionated in a fraction containing 
pure platelets and a mononuclear cell frac­
tion containing only 3% granulocytes.
In the present communication it is shown 
that the BCS is also perfectly suited for the 
isolation of hematopoietic progenitor cells 
from bone marrow cells.
Materials and Methods
Bone Marrow Aspiration 
Bone marrow was harvested for cryopreservation 
under general or epidural anesthesia from the posterior 
iliac crests of 9 patients (acute leukaemia in first rem­
ission) in disposable syringes (10 ml) containing 1ml 
acidic citrate dextrose (ACD) and 50IU preservative 
free heparin. The marrow was filtered (70|im pore size) 
and collected in transfer bags. 100-150 ml (10%) of the 
bone marrow suspension was separated as described 
below. The remainder was processed routinely by 
means of a haemonetics model 30 cell separator and 
cry op reserved, as described previously [Van de Ouwe- 
land el al., 1982],
Cell Separation
A buffy coat was prepared from bone marrow aspi­
rates by means of a recently developed BCS [Figdor et 
al, 1982a], This sandglass resembling apparatus was 
made of glass and consists of an upper (180 ml) and 
lower (150 ml) compartment connected by a narrow 
tube. The device was filled with 100-150 ml of a bone 
marrow suspension that was diluted with an equal vol­
ume of phosphate-buffered saline containing 15% ACD. 
In some experiments we added to this suspension 10% 
Plasmasteril (Fresenius, Bad Homburg, FRG), which 
contained 6% hydroxyethyl starch (HES) as a rouleau- 
forming agent.
The volume of the lower compartment of the BCS 
was adjusted to the hematocrit in such a way that after 
centrifugation (30min, 500g at room temperature) the 
buffy coat was formed just below the narrow tube 
(fig. la).To this end we injected Maxidens (MD; Nye- 
gaard and Co., Oslo, Norway) into the lower compart­
ment, MD is a nontoxic autoclavable fluid that is 
immiscible with aqueous solutions and has a density of 
1.9g/mL The volume of MD required could be calcu­
lated after determination of the hematocrit of the bone 
marrow suspension. After centrifugation, a fractiona­
tion device is screwed on top of the apparatus (fig, lb). 
Fractionation is accomplished by the simultaneous in­
troduction of NaCl in the upper compartment and md 
in the lower compartment. This procedure has the 
advantage that the plasma acts as a sheath flow sur­
rounding the buffy coat cells, and thus prevents sticking 
of these cells to the wall of the outlet tube. In addition 
the buffy coat cells were collected in autologous plasma. 
Five fractions were collected at the outlet. Fractions 1-4 
had a volume of 5 ml each, fraction 5 which contained 
the remaining RBC layer and the plasma had a volume 
of 1.80-280 ml.
The whole procedure including centrifugation and 
collection of the various fractions took less than 
90min.
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Figl. The blood component separator (in cross- 
section) is filled with bone marrow and centrifuged A, 
After centrifugation the buffy coat (BC) cells are iso­
lated (B) by the simultaneous introduction of NaCl and 
MD, The flow of NaCl and MD is generated by means 
of hydrostatic pressure. Pa=Plasma.
Cell Counting and Morphology 
The number of RBC and nucleated cells (NC) was 
determined by means of a Coulter Counter Model ZF 
(Coulter Electronics Ltd, Dunstable, Beds., UK).
The morphology was examined on cy to centrifuge 
preparations after staining with May-Griinewald 
Giemsa.
Committed Stem Cell Assays 
Granulocyte-macrophage colony forming cells 
(GFU-GM) and erythroid colony forming cells (BFU- 
E) were determined as described previously [De Witte et 
al., 1984]. Briefly, the number of GFU-GM was deter­
mined after incubation of 1-2x105 cells in 2 ml semi­
solid agar (Difco) containing 4% placenta conditioned 
medium and 20% fetal calf serum (FCS) for a period of 
10-12 days. Aggregates of 40 and more cells were 
counted as colonies.
The number of BFU-E was determined by incubat­
ing 1x105 cells/ml in Iscove’s modified Dulbecco’s 
medium (IMDM, Gibco 78-5220) containing 0.8% 
methlylcellulose (Fluka, Schweiz), 10~4 M  thyoglyce- 
rol, 10% BSA (Sigma), 20% FCS (Rehatain), 20% leu­
kocyte conditioned medium and 2 units sheep erythro­
poietin (Connaught Medical Research Laboratories). 
Orange to red colonies of at least three subclusters or 
one single colony of more than 300 cells were scored as 
BFU-E on day 14 of the culture. Before culture, a sam­
ple of the original bone marrow suspension and fraction 
five were centrifuged over Ficoll/Isopaque with a den­
sity of 1,085 to remove most of the RBC.
Results
Bone marrow was aspirated from acute 
leukemia patients in first remission. 
100-150 ml of the bone marrow suspension 
which contained 980-1,870xl06 NC was 
centrifuged in the BCS and fractionated into 
five fractions. The buffy coat was isolated in 
fractions 1-3, fraction 4 was an intermediate 
fraction, and fraction 5 contained both the 
remaining plasma and the RBC layer (in­
cluding the remaining granulocytes). These 
5 fractions cotained 95 ±7% of the NC. The 
distribution of the NC in the various frac­
tions is shown in Figure 2a. The number of 
NC/ml (fig. 2b) gradually decreased from 
751± 34x l06/ml in fraction 1 to only 
2 ± 0 .5 x l0 6/ml in fraction 5. The RBC/NC 
ratio which is shown in figure 2c indicates
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Fig. 3. Recoveries of the NC, RBC, CFU-GM and 
BFU-E in the buffy coat (fraction 1.-3) of the bone mar­
row aspirates. Mean ±  SD of 9 experiments.
Fig 2. Absolute cell counts and RBC/NC ratios of 
the various fractions, a Distribution of the NC in the 
various fractions, b Number of NC/ml. c RBC/NC ratio 
was calculated to determine the RBC contamination, d
Distribution of the CFU-GM in the various fractions. The buffy coat which was collected in the 
Unfractionated bone marrow contained 1,450±450 first three fractions contained 64 ±  8%  of the
x 106NC (11.7 ±  3.lxl06/ml). The RBC/NC ratio was ]\jc(fig. 3). Furthermore, it is shown in figure
162 + 68 and the unfractionated marrow contained -  ^ , re * • j  m  i ¿n/ c
421 + 168xl03 CFU/GM ^ ^ a t  y  C c o n t a m e d  91 ±  6% o f
the CFU-GM and 87 ±  9% of the BFU-E 
initially present in the bone marrow suspen­
sion. In addition the buffy coat was contam- 
that the RBC contamination was very low in inated with only 6 ±  2% of the RBC and 
the first three fractions. The RBC/NC ratio 46 ±  8% of the granulocytes initially present 
increased from 10 ±  4 in fraction 1 to in the original bone marrow aspirate 
540 ±  105 in fraction 5. The distribution of (fig. 3).
the hematopoietic progenitor cells (CFU- In some experiments we added HES to
GM)> which is shown in figure 2d, demon- the bone marrow suspension prior to centri­
strated that most of the CFU-GM were re- fugation. The results obtained with these
covered in fractions 1, 2 and 3. bone marrow suspensions did not differ sig-
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myelocytes were distributed equally over 
fractions 1-5. The number of granulocytes 
gradually increased with the fraction num­
ber, while in contrast the majority of the 
lymphocytes (91 ±5%) and monocytes 
(89 ±8%) was recovered in fractions 1-3. 
The normoblasts were distributed equally 
over all five fractions.
Discussion
The aim of the present study was to inves­
tigate whether the BCS could be used for the 
isolation of hematopoietic progenitor cells 
by preparing a buffy coat from human bone 
marrow. The results demonstrated that ap­
proximately 90% of the CFU-GM and BFU- 
E could be isolated in a buffy coat (fraction 
1-3) in a volume of only 10-15% of the orig­
inal bone marrow aspirate. In addition the 
buffy coat contained more than 90% of the 
mononuclear cells and only 6 ±  2% and 
46 ± 8% of the RBC and granulocytes, re­
spectively.
The addition of a rouleau-forming agent 
to the bone marrow suspension did not re­
sult in a better separation. Furthermore we 
found that the optimal temperature to sepa­
rate bone marrow with the BCS was 
25-30 °C (not shown).
The results obtained with the BCS are 
comparable to those obtained with semicon- 
nificantly from experiments carried out tinuous or continuous blood cell separators 
without the addition of HES (results not [W^meretal., 1977; VandeOitwelandet&l,,
bm 1 bm 1
fraction
F ig  4 .  Morphological characterization of the vari­
ous bone marrow fractions after staining with May- 
Griinwald Giemsa, Mean +  SD of 5 experiments.
shown). 1982; Gilmore et al., 1983]. The BCS is a
The morphological characterization of simple and inexpensive apparatus and has
the cells in the various fractions is shown in the advantage that it can be used in normal
figure 4. Both myeloblasts and promyelo- blood bank centrifuges. It does not need spe-
cytes were highly enriched in fractions 1-3 daily trained personnel and could therefore
(9 5 ±4% were recovered in fractions 1-3, also be applied in the smaller medical cen-
respectively) while myelocytes and meta- ters.
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Bone marrow may be manipulated in vi­
tro prior to infusion into the patient: either 
to remove T cells from allogeneic bone mar­
row in order to prevent graft-versus-host dis­
ease [Filipovich et al.5 1982; Prentice et al., 
1982], or to remove tumor cells that contam­
inate autologous bone marrow from cancer 
patients [Buckman  et al., 1982; Treleaven et 
al.3 1984]. To obtain optimal results it is 
essential to concentrate the bone marrow 
progenitor cells as much as possible prior to 
in vitro manipulation. For this purpose the 
BCS seems to be suited extremely well.
Until now the prototype of the BCS used 
in this study can process a volume of up to 
150 ml of bone marrow aspirate. However, 
volumes that have to be processed for clini­
cal use ( bone marrow transplantations) are 
much larger, 800-1,200 ml in general. 
Therefore, we recently started the develop­
ment of a larger and disposable version of the 
BCS by means of which volumes of up to 
600 ml can be separated and that also fits in a 
bucket of a normal blood bank centrifuge.
In our opinion a clinically applicable ver­
sion of the BCS might further complete the 
scale of techniques currently available to 
separate bone marrow, since it allows the 
efficient isolation of bone marrow progeni­
tor cells under sterile conditions by simple 
means.
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